Announcement PDF ASX Announcement DEP® HER2 Investor Webinar Melbourne, Australia; 7 July 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with experience in advancing dendrimer technology from the lab to the patient, today held an investor webinar focusing on the DEP® HER2 preclinical data package and the company’s plan for clinical development. The slides for the webinar are appended with this announcement. A recording of the webinar will be made available on Starpharma’s website. About Starpharma Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications. Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn. Investor & Media Relations Gabriella Hold gaby@thecapitalnetwork.com.au Starpharma Holdings Limited Cheryl Maley, Chief Executive Officer Justin Cahill, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward-Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® HER2 preclinical data, clinical pathway and why this opportunity matters I N V E S T O R W E B I N A R July 2026 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors. 2 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 Disclaimer and forward-looking statements I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 3 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 DEP® stands for Dendrimer Enhanced Product Investment Highlights Global leader in dendrimer technology Clinically Validated DEP® Technology Platform Novel Radio- pharmaceutical Asset • DEP® HER2 in 3L HER2+ Gastric Cancer - FIH / Ph 1 clinical study 2H CY26 • No approved 3L therapies • Up to ~US$2.5bn market opportunity in HER2+ gastric cancer Three Strategic, High-value, Partnerships Positioned for Next Generation Therapies Portfolio of Partner- ready Assets • Over 20 years of dendrimer technology capabilities • Strategically managed and actively maintained patent portfolio • More than 350 patients treated with DEP® across multiple clinical programs • Two commercial consumer health products across 35+ markets Strong IP & Uniquely Experienced Team • Partnerships with Genentech, Medicxi, and Radiopharm Theranostics • Diversified source of upside with significant potential • DEP® Platform uniquely positioned to enhance efficacy and safety profile of emerging, high value modalities, focusing on targeted oncology therapies • Phase 2 assets: DEP® SN38 and DEP® Cabazitaxel • Demonstrated efficacy and safety profile relative to SoC I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® Platform Developing Targeted Therapies Through Dendrimer Technology 4 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 G2 G3 G4 G5 Overview • Extensive pharmaceutical dendrimer dataset backed by 20 years of IP and know-how • Clinically validated with over 350 patients treated across multiple clinical programs  Proprietary DEP® technology to customise payloads drugs and/or targeting moieties to overcome the most significant challenges in drug development (efficacy, toxicity, pharmacokinetics) • Demonstrated platform with favourable results across two phase 2 trials of DEP® SN38 and DEP® Cabazitaxel Broad application across a range of treatment modalities Our DEP® Platform Technology Global leader in dendrimer technology Dendrimer Generations 5 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Challenges in RLT DEP® Dendrimer Solution Limited tumour uptake, target binding and/or retention Suboptimal PK profile – too long or too short circulation Organ (kidney) uptake, retention and dose- limiting toxicities ✓ Optimal targeting moiety and radionuclide ✓ Multivalent presentation of functional surface groups (targeting moiety, PEG, payload) ✓ Tuneable PK with adjustable size and PEG shielding ✓ Optimal biodistribution with reduced kidney uptake and retention Enhanced Efficacy Enhanced Safety Leveraging DEP®’s Competitive Advantage to Address Key Radiotherapy Challenges DEP® delivers clear benefit in radioligand therapy 6 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 • Rapid tumour binding • Rapid accumulation and retention (increased penetration in the tumour site) • Minimised off-target effects • Rapid blood clearance • Reduced kidney retention I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 7 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Treatment paradigm + unmet need (HER2+ Stage 3-4 metastatic) 1L (HER2+ metastatic/ advanced) 2L (after trastuzumab- based regimen) 3L+ (post-T-DXd) Trastuzumab (Herceptin®) + chemotherapy backbone (ToGA): Trastuzumab deruxtecan (T-DXd/Enhertu®): No FDA-approved treatments DEP® HER2-Lu opportunity Trastuzumab (Herceptin®) Trastuzumab deruxtecan (Enhertu®) 1st Line 2nd Line Median Progression Free Survival (PFS) 6.7 months 5.6 months Median Overall Survival (OS) 13.8 months 12.5 months >36% of patients are diagnosed in advanced stage Low 5-year survival rate for advanced gastric cancer1 HER2 in gastric/GEJ cancer • HER2 positivity is ~22% across screened gastric/GEJ tumour samples (with variation by subtype and site) Disease burden • ~968k new gastric cancer cases and ~660k deaths globally (2022) • Outcomes remain poor in advanced disease Strategic expansion: Opportunity for expansion to HER2-low indications including: • Metastatic breast cancer (mBC) Intended entry point: locally advanced/metastatic HER2+ gastric/GEJ cancers Significant Unmet Patient Need in HER2+ Gastric Cancer Uncontested opportunity in 3L treatment resistant HER2+ Gastric Cancer 7.5% 1. SEER 5-Year Relative Survival Rates, 2015-2021 Addressable market for HER2+ mBC & gastric/GEJ cancers: ~$17bnby 2030 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 8 Preclinical Package Overview, Clinical Pathway, and Expert Perspective DEP® HER2 Preclinical Data I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® HER2-lutetium is a Targeted Radioligand Therapy Leveraging Dendrimer Technology First-in-class HER2 Radiotherapy Differentiated profile with potential to enhance tumour targeting and tolerability DEP® HER2-lutetium Optimised Design: Parameter Target Product Profile Tumor Uptake Fast tumour accumulation Tumor Retention Retention in tumor >48h Renal Clearance Fast clearance, minimal accumulation Blood Clearance Effective clearance from blood / bone marrow by 48h Efficacy HER2high and HER2low expressing tumors Indications HER2 expressing cancers (gastroesophageal, breast, etc.) HER2-targeting nanobody (VHH) Surface PEG DOTA-Lutetium-177 DEP® Dendrimer Scaffold DEP® HER2-lutetium Schematic 9 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Biodistribution is Controlled by Dendrimer Design DEP® radioligand therapy – customisable, optimised biodistribution 0 40 68Ga, dynamic PET/CT (0-3h), naïve (non-tumour-bearing) mice Smaller Dendrimer Larger Dendrimer Kidney Excretion Longer Circulation Time 10 DEP® Dendrimer Platform Provides the Ability to Tailor Biodistribution Signal Intensity 10 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 MW (kDa) DEP® HER2-lutetium Optimised size, biodistribution, activity and tolerability I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 T = SKOV3 (HER2+) tumour K = kidneys 4 hours T DEP® HER2-Lu T HER2-VHH-Lu 48 hours T T K K 5 days T T 12 days T T K DEP® HER2-lutetium Achieves Strong Uptake & Retention in HER2+ Tumors Strong tumour uptake and prolonged tumour retention with low kidney exposure DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu DEP® HER2-Lu HER2-VHH-Lu 2D SPECT imaging showing actual radiation signal (intensity) over time (Images not corrected for decay). SKOV3 is a HER2-high expressing cancer cell line. Mice (n=3 per group) dosed with 15 MBq of radioactivity.One representative mouse is shown per group per timepoint. • DEP® HER2-Lu vs. radiolabelled HER2-targeting VHH without dendrimer, HER2-VHH-Lu 11 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 0 48 96 144 192 240 288 0 10 20 30 40 50 Time post-dose (hours) Radioactivity (%ID/g) Ex vivo biodistribution, SKOV3 tumour-bearing mice, n=3 per timepoint dosed with 15 MBq radioactivity; ID/g = injected dose (radioactivity) per gram of tissue; data are mean ± SEM DEP® HER2-Lu Blood Clearance Fast clearance from blood (%ID/g) Ratio in Tumour vs. Tissue 48 hours 5 days 12 days (%ID/g) 48 hours 5 days 12 days Strong tumour uptake and prolonged retention Low kidney exposure DEP® HER2-lutetium Achieves Strong Uptake & Retention in HER2+ Tumors Fast blood clearance, minimal kidney exposure and favourable tumour to tissue ratios DEP® HER2-Lu Biodistribution Tumour radioactivity ~150 times higher than blood Radioactivity in the tumour vs: 12 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 0 10 20 30 40 50 60 0 20 40 60 80 100 Time post-dose (Days) Survival (%) *** * ** 13 0 10 20 30 40 50 0 500 1000 1500 Time post-dose (Days) Tumor volume (mm 3 ) *** DEP® HER2-lutetium Achieves Significant Anti-tumour Activity and Survival Benefits Durable tumour growth control and survival benefits that are comparable to Enhertu® Mice (n=8 per group) dosed IV on Day 0. SKOV3 is a HER2-high expressing cancer cell line. Tumour volume curves displayed until volume of tumour in the first mouse in each group reaches volume endpoint (1500 mm3). Study terminated Day 57. Tumour volume data are mean ± SEM and analysed by ordinary one-way analysis of variance (ANOVA) with Dunnett’s multiple corrections on tumour growth inhibition (Day 21-Day 0) at Day 21. ***P<0.001 for DEP® HER2-Lu (15 and 25 MBq) and T-DXd (Enhertu®) vs Vehicle (phosphate buffered saline, PBS) and HER2-VHH-Lu. Survival data are analysed by Logrank (Mantel-Cox)test between two groups. *P<0.05, **P<0.01 and ***P<0.001 for each group vs. Vehicle and HER2-VHH-Lu. Anti-tumour Activity Survival Benefit DEP® HER2-Lu (25 MBq) DEP® HER2-Lu (25 MBq) 50% survival @d57 Enhertu® (10 mg/kg) 12.5% survival @d57 • HER2-positive (high-expressing) cancer model; DEP® HER2-Lu (25 MBq) and DEP® HER2-Lu (15 MBq) vs. Enhertu®, HER2-VHH-Lu and Vehicle (PBS, saline) 13 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 14 0 20 40 60 80 100 0 20 40 60 80 100 Time post-dose (Days) Survival (%) * * 0 20 40 60 80 100 0 500 1000 1500 2000 Time post-dose (Days) Tumor volume (mm 3 ) **** ** * 14 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 DEP® HER2-lutetium Benefits Extend to HER2-low expressing tumours Findings support future evaluation across a broader HER2-expressing patient population Mice (n=8 per group) dosed IV on Day 0. Capan-1 is a HER2-low expressing cancer cell line. Tumour volume curves displayed until volume of tumour in the first mouse in each group reaches volume endpoint (2000 mm3). Study terminated Day 84. Tumour volume data are mean ± SEM and analysed by ordinary one-way analysis of variance (ANOVA) with Dunnett’s multiple corrections on tumour growth inhibition (Day 25-Day 0) at Day 25. *P<0.05 for DEP® HER2-Lu (15 MBq), **P<0.01 for DEP® HER2-Lu (25 MBq) and ****P<0.0001 for T-DXd (Enhertu®) vs Vehicle (phosphate buffered saline, PBS). Survival data are analysed by Logrank (Mantel-Cox)test between two groups. *P<0.05 for each group vs. Vehicle. Anti-tumour Activity – HER2-low Survival Benefit – HER2-low DEP® HER2-Lu (25 MBq) 87.5% survival @d84 Enhertu® (10 mg/kg) 62.5% survival @d84 • HER2-low expressing cancer model; DEP® HER2-Lu (25 MBq) and DEP® HER2-Lu (15 MBq) vs. Enhertu® and Vehicle (PBS, saline) I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® HER2-lutetium Preclinical Summary A novel, radiopharmaceutical asset targeting cancers with high unmet need 15 DEP® HER2-lutetium Radioligand Therapy (RLT) Asset Dendrimer-based nanobody radioligand targeting HER2-expressing cancers (gastric & metastatic breast) with high unmet need Optimized Biodistribution • Fast blood clearance and minimal kidney accumulation • Strong tumor uptake and retention in HER2high and HER2low models Efficacy • Significant tumor reduction and survival benefit vs. control (HER2high [SKOV3], HER2low [Capan-1] mouse models) Safety • Favorable tumor-to-tissue ratios and low off-target toxicity Key Differentiators 1 Potential first radioligand therapy for HER2-expressing tumors 2 Nanobody-dendrimer format: • High tumor uptake • Low kidney uptake • Rapid blood clearance 3 Broad application across HER2high and HER2low expressing tumors 15 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Clinical Development Strategy Significant unmet need offers potential for Accelerated Approval FIH / Phase 1 (Imaging, dosimetry, and mass dose determination – Up to 15 patients) Phase 1/2 (Dose escalation/confirmation, expansion cohorts, efficacy, safety, up to 40 patients) Pivotal Study Phase 2/3 (Registrational, potential Fast Track – up to 250 patients) FDA Type B Pre-IND Meeting Registration H2 CY26 First patient dosed H2 CY27 Topline readout for up to 15 patients from FIH/Ph 1 Ph 1/2 (IND) begins H1 CY27 Initial data readout First 3-4 patients CY28 Phase 2/3 ready POTENTIAL FOR ACCELERATED APPROVAL 16 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 Objectives • Confirm tumour targeting • Optimise mass-dose and biodistribution • Assess safety, PK and dosimetry Endpoints • PK and tumour uptake • Biodistribution / dosimetry • Safety & tolerability Next Steps • First patient H2 CY26 • Initial data H1 CY27 • Topline Phase I data H2 CY27 • Pre-IND/IND • Advance to Phase 1/2 expansion cohorts First-in-human Phase 1 Clinical Study I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Insert speaker name and title here 17 17 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 18 Consistent Results Across Multiple Oncology Targets DEP® Platform Exemplification I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® Radiopharmaceutical Platform Exemplified Across Multiple Targets HER2-targeted lead asset supported by broader platform exemplification and strong IP position Cross-target DEP® biodistribution dataset • Exemplification of the DEP® radiopharmaceutical platform across multiple oncology targets, including PSMA and EGFR • Cross-target data support the modularity of the DEP® approach and its potential application across multiple targeting strategies • A new patent application covering DEP® dendrimer technology in radioligand therapy strengthens Starpharma’s platform IP position Insert speaker name and title here 19 vivo Biodistribution at 48h Radioactivity (%ID/g) DEP® HER2 DEP® PSMA DEP® EGFR DEP® HER2 is the lead clinical opportunity, with HER2, PSMA and EGFR data collectively supporting a broader, IP-protected radiopharmaceutical platform 19 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Cross-Target Data Support Broad DEP® Platform Opportunity HER2, PSMA and EGFR constructs show tumour-focused biodistribution and favourable tumour-to-tissue profiles • Consistent tumour uptake observed across HER2-, PSMA- and EGFR-targeted DEP® constructs • Favourable tumour-to-tissue ratios observed across key healthy tissues • Body-weight data provide supportive tolerability context over the observed period • Cross-target consistency supports broader DEP® platform potential Insert speaker name and title here 20 Tumor Kidney Liver Lung Spleen Muscle 0 10 20 30 ex vivo biodistribution - 48h post dose Radioactivity (%ID/g) DEP® HER2 DEP® PSMA DEP® EGFR Kidney Liver Lung Spleen Muscle 0 10 20 30 Radioactivity (%ID/g) Ratio in Tumor vs. Tissue DEP® HER2 DEP® PSMA DEP® EGFR Tumour to tissue ratio - 48h post-dose D0 D2 D5 D6 D8 D12 80 90 100 110 120 Body Weight Time post-dose (Days) Body weight (% of baseline) DEP® EGFR DEP® HER2 DEP® PSMA 20 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 DEP® Radiopharmaceutical Data Supports New Patent Filing Insert speaker name and title here 21 21 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 Differentiated preclinical profile strengthens platform IP and partnering potential Differentiated Profile • Enhanced tumour uptake and retention • Low off-target and kidney exposure • Rapid blood clearance and renal excretion Broad, Modular Platform • Consistent data observed across HER2, PSMA and EGFR • Potential for an improved therapeutic window • Applicable across multiple tumour types ~US$8bn → ~US$15bn Global radiopharmaceutical market by 2030* Radiopharmaceuticals are one of the fastest-growing areas of precision oncology, attracting significant strategic interest and partnering activity from global pharmaceutical companies. IP & Partnering Upside • New patent filed for DEP® in radioligand therapy • Protects the DEP® technology across multiple targets • Supports parallel partnering programs * https://www.marketsandmarkets.com/Radiopharmaceuticals-market-research-255.html I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 22 Scientific Advisors and Strategic Partners Global Radiopharmaceutical Experts 22 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 Scientific & Clinical Advisors: Strategic RLT Partners: Elisabeth (Liesbeth) de Vries, M.D., Ph.D. • Professor of Medical Oncology, University Medical Center Groningen (UMCG), Netherlands • Molecular imaging, breast cancer drug research, HER2- targeted imaging and therapy Gary A. Ulaner, M.D., Ph.D., F.A.C.N.M • James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy, Hoag Family Cancer Institute; Clinical Prof. Radiology & Cancer Biology, Keck School of Medicine, USC; President-Elect of SNMMI • Molecular imaging and theranostics; pioneer in PET radiotracers Tony Lahoutte, M.D., Ph.D. • Physician & Head of the Dept. of Nuclear Medicine, UZ Brussel; Head of Molecular Imaging and Therapy Research at Vrije Universiteit Brussel; • Co-founder of RLT companies • Nanobody-based imaging, radionuclide therapy expert Tracer CRO • RLT CRO focused on first-in-human trials using nuclear & optical molecular imaging • Optimal clinical trial design via streamlined biodistribution and imaging studies; EMA/FDA-compliant early human data for oncology assets Bracken Group • Life science consultancy with deep expertise in radiopharmaceutical regulatory strategy, development, clinical trial design and operations • Strategic regulatory and clinical advisors University of Qld/ AMTAR • The AMTAR Hub, an ARC- funded research centre at University of Queensland, is focused on developing manufacturing technologies for targeted radiopharmaceuticals • Prof. Kristofer Thurecht & colleagues support Starpharma’s DEP® radiotheranostics program through AMTAR, contributing expertise in translational radiopharmaceutical development.† Yelena Janjigian, M.D. • Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center; Professor at Weill Cornell • Gastric and esophageal cancers; immunotherapy and HER2-targeted strategies; translational research and global clinical trial leadership † Work conducted under the AMTAR collaboration was supported by the Australian Government through the Australian Research Council (IH220100017) I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Insert speaker name and title here 23 Professor Tony Lahoutte, MD, PhD Physician and Head of the Department of Nuclear Medicine, University Hospital (UZ), Brussel Head of Molecular Imaging and Therapy Research (MITH) at the Vrije Universiteit Brussel (VUB) in Belgium Co-founder of companies developing targeted radioligand therapies Expertise includes nanobody-based imaging, radionuclide therapy 23 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 KOL Perspective – Professor Tony Lahoutte I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Q&A 24 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Upcoming Catalysts • Commencement of the Phase 1 study in H2 CY2026 • Early clinical data, particularly safety, biodistribution, dosimetry and tumour uptake in 1H CY2027 • Topline data from FIH Phase 1 in H2 CY2027 • Continued progress in the broader DEP® radiopharmaceutical platform • Expansion of partnership opportunities DEP® Radio Milestones What to expect in the following 12-18 months 25 I N V E S T O R W E B I N A R J U L Y 2 0 2 6 Phase 1 Start H2 CY2026 Early Clinical Data 1H CY2027 Topline Data CY2027 Platform & Partnerships Ongoing I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6 Thank you Investor Relations Investor.Relations@Starpharma.com www.starpharma.com Corporate Office 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia